Global Biosimilars Market – Products, Applications and Regulations

January 2021 •
356 pages •
Report ID: 5775825 •
Format: PDF

Summary
Table of contents

Report Synopsis
Due to the COVID-19 Pandemic, telehealth and tele-detailing (also called remoter detailing or web calls) have set forth that allow a biosimilars companies’ commercialization branch to have a wide range with less few reps. Also, the fluidity of the labor market is another new dynamic allowing for a greater diversity of commercialization build-out models. These new dynamics greatly change how companies should be building models of commercialization that also has vast implications for potential BD partnerships. The solution to ‘build versus buy’ is no longer driven by the size, scale, and cost of a sales force leading to outdated product P&L’s. However, a hybrid solution that a partial build plus skilled, experienced contractors plus CSO for sales reps will be the optimal solution. This hybrid model could allow for greater biosimilar uptake and more efficient uptake.

Global market for Biosimilars is dominated by Oncology, estimated at US$5.4 billion (38.6% share) in 2020, which is anticipated to post the slowest CAGR of 29% between 2020 and 2026 and reach a projected US$24.8 billion by 2026.

Research Findings & Coverage
• Global Biosimilars market is analyzed in this report with respect to key product types and major therapeutic areas
• The study exclusively analyzes the market for each product type and therapeutic area of Biosimilars by all major geographic regions/countries globally
• mAbs - All the Rage in Biosimilars’ New Wave
• Patent Expirations of Major Biologics Leads Way for Biosimilars
• Role of Biosimilars in Continuous Manufacturing (CM) Development and Innovation
• Availability of Biosimilar May Affect Biologic Drug Pricing
• Key business trends focusing on product innovations/developments, M&As, JVs and other recent industry developments
• Major companies profiled – 36
• The industry guide includes the contact details for 155 companies

Product Outline
The report analyzes the market for the following key product types of Biosimilars:
• Monoclonal Antibodies (mAB)
• Erythropoietin (EPO)
• Granulocyte Colony-Stimulating Factor (G-CSF)
• Insulin
• Others (includes Interferons, Follitropins, Recombinant Proteins etc.)
Therapeutic areas of Biosimilars analyzed in this study comprise the following:
• Oncology
• Autoimmune Disorders
• Blood Disorders
• Growth Hormone Deficiency
• Others (includes Chronic Diseases, Infectious Diseases, Cardiovascular Disorders etc.)

Analysis Period, Units and Growth Rates
• The report reviews, analyzes and projects the global Biosimilars market for the period 2017-2026 in terms of US$ and the compound annual growth rates (CAGRs) projected from 2019 through 2026

Geographic Coverage
• North America (The United States, Canada and Mexico)
• Europe (Germany, the United Kingdom, France, Spain, Italy and Rest of Europe)
• Asia-Pacific (China, India, Japan, South Korea and Rest of Asia-Pacific)
• Rest of World (Brazil, Israel and Other Rest of World)

Ahmad helps you find the right report:

+1 718 618 4302
Contact by email

FAQ

Testimonials

The market research advisor answered my questions quickly and professionally. ReportBuyer's team did their best to ensure that I felt comfortable before making the investment to purchase the report.

Cristian Nunez

Director of Corporate Development Chugach Alaska Corporation

My overall experience with ReportBuyer today has been very positive, and I must thank you for your patience (...). Also, the sample you sent me and the explanations provided were very helpful.

D. Lescuyer

Executive Vice President Oral Business at Skyepharma

The research specialist was very helpful, and proposed the best content for my needs. ReportBuyer also offered a great follow-up, thanks for everything !

P. Thompson

EMEA Managing Director

We were satisfied with the support that ReportBuyer's team provided. Thanks to their recommendations, the report we purchased provided exactly what we want.

Y. Wang

Business Analyst

We didn't have time to do the research internally, and thanks to ReportBuyer's team we were able to find the appropriate data.

S. Chen

Research Coordinator

I was impressed by the customer service: it was fast, responsive, and 100% professional !

D. Krivan

Market Research Analyst

The research specialist provided prompt and helpful service. He also followed up to ensure I had all the information to deliver my business development plan.

C. Adams

Senior Business Development Manager